Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. [electronic resource]
- Ophthalmology Jun 2006
- 992-1001.e6 p. digital
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1549-4713
10.1016/j.ophtha.2006.02.027 doi
Aged
Aged, 80 and over
Aptamers, Nucleotide--adverse effects
Choroidal Neovascularization--drug therapy
Double-Blind Method
Female
Fluorescein Angiography
Humans
Injections
Intraocular Pressure--drug effects
Macular Degeneration--complications
Male
Middle Aged
Prospective Studies
Treatment Outcome
Vascular Endothelial Growth Factor A--antagonists & inhibitors
Visual Acuity--drug effects
Vitreous Body
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1549-4713
10.1016/j.ophtha.2006.02.027 doi
Aged
Aged, 80 and over
Aptamers, Nucleotide--adverse effects
Choroidal Neovascularization--drug therapy
Double-Blind Method
Female
Fluorescein Angiography
Humans
Injections
Intraocular Pressure--drug effects
Macular Degeneration--complications
Male
Middle Aged
Prospective Studies
Treatment Outcome
Vascular Endothelial Growth Factor A--antagonists & inhibitors
Visual Acuity--drug effects
Vitreous Body